Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Dana–Farber Cancer Institute
Boston, Estados UnidosDana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (142)
2024
-
A road map for the treatment of pediatric diffuse midline glioma
Cancer Cell
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 9, pp. 2706-2732
-
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines
European Journal of Nuclear Medicine and Molecular Imaging
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
2023
-
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis from the Randomized Phase II ELOQUENT-3 Trial
Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 568-578
-
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
The New England journal of medicine, Vol. 389, Núm. 11, pp. 1009-1022
-
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Gynecologic Oncology, Vol. 178, pp. 119-129
-
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study
Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1921-1932
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Obstetrical and Gynecological Survey
-
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
ESMO Open, Vol. 8, Núm. 4
-
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Seminars in Hematology
-
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Seminars in Hematology
-
Safety and management of niraparib monotherapy in ovarian cancer clinical trials
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 971-981
-
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial
JAMA Oncology, Vol. 9, Núm. 12, pp. 1688-1695
-
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8
-
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Annals of Oncology